First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer—the randomised METIMMOX trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer—the randomised METIMMOX trial ; volume:130 ; number:12 ; day:25 ; month:4 ; year:2024 ; pages:1921-1928 ; date:6.2024
British journal of cancer ; 130, Heft 12 (25.4.2024), 1921-1928, 6.2024
- Urheber
-
Ree, Anne Hansen
Šaltytė Benth, Jūratė
Hamre, Hanne M.
Kersten, Christian
Hofsli, Eva
Guren, Marianne G.
Sorbye, Halfdan
Johansen, Christin
Negård, Anne
Bjørnetrø, Tonje
Nilsen, Hilde L.
Berg, Jens P.
Flatmark, Kjersti
Meltzer, Sebastian
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41416-024-02696-6
- URN
-
urn:nbn:de:101:1-2408271244533.840813250386
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ree, Anne Hansen
- Šaltytė Benth, Jūratė
- Hamre, Hanne M.
- Kersten, Christian
- Hofsli, Eva
- Guren, Marianne G.
- Sorbye, Halfdan
- Johansen, Christin
- Negård, Anne
- Bjørnetrø, Tonje
- Nilsen, Hilde L.
- Berg, Jens P.
- Flatmark, Kjersti
- Meltzer, Sebastian
- SpringerLink (Online service)
Ähnliche Objekte (12)
Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis
Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial
Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
Metastatic Merkel cell carcinoma response to nivolumab
Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study
Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma
Erratum to: Metastatic Merkel cell carcinoma response to nivolumab
Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study
Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis
Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial
Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
Metastatic Merkel cell carcinoma response to nivolumab
Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study
Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma
Erratum to: Metastatic Merkel cell carcinoma response to nivolumab
Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study
Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis
Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial
Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
Metastatic Merkel cell carcinoma response to nivolumab
Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study
Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma
Erratum to: Metastatic Merkel cell carcinoma response to nivolumab
Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study
Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab